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How to break bad news: State-of-the-art of letting go
C. Rodriguez Cerdeira1, A. Molares Vila2, V. Mun˜oz Garzón3
1 Chuvi. Vigo, Dermatología, Spain
2 Universidad de Vigo, Departamento de Química Analítica, Spain
3 Chuvi. Vigo, Servicio de Oncología Radioterápica, Spain
Regarding the cancer diagnosis, the majority of patients have information needs, want to be involved in treatment decisions
and know their prognosis. The difﬁculty for physicians is how to meet individual information needs, give hope, but not deliver
unrealistic expectations. Information that drastically alters the life world of the patient is termed as bad news. Conveying bad
news is a skilled communication, and not at all easy. The amount of truth to be disclosed is subjective. A properly structured
and well-orchestrated communication has a positive therapeutic effect. This is a process of negotiation between patient and
physician, but physicians often ﬁnd it difﬁcult due to many reasons. They feel incompetent and are afraid of unleashing a
negative reaction from the patient or their relatives. The physician is reminded of his or her own vulnerability to terminal
illness, and ﬁnd themselves powerless over emotional distress. Lack of sufﬁcient training in breaking bad news is a handicap
to most physicians and health care workers. Adherence to the principles of client-centered counseling is helpful in attaining
this skill. Fundamental insight of the patient is exploited and the bad news is delivered in a structured manner, because the
patient is the one who knows what is hurting him most and he is the one who knows how to move forward. Six-step SPIKES
protocol is widely used for breaking bad news. In this presentation, we put forward more six-step protocol, the BREAKS protocol
as a systematic and easy communication strategy for breaking bad news. Development of competence in dealing with difﬁcult
situations has positive therapeutic outcome and is a professionally satisfying one.
http://dx.doi.org/10.1016/j.rpor.2013.03.569
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Introduction. Sebaceous carcinoma is a rare malignancy derived from adnexal epithelium of sebaceous glands. It usually occurs
in the eyelids, but can occur extraocular (head and neck (75%), followed by the trunk (15%) and extremities (10%)). Diagnosis is
difﬁcult because no typical characteristics and histopathology can resemble squamous cell carcinoma or basal cell carcinoma.
It is an aggressive neoplasm that metastasizes up to 25% of cases and has a high mortality.
Case report. Male 30 years, smoker, painter by profession and allergy to iodinated contrast, presenting Left parietal lesion excised in
2004, with histologically sudoríparo hidradenoma. Relapse and progressive growth presents new performing in MAY/05 excision.
In TAC skull-cervico-thoracic lymph nodes reported bilateral laterocervical <1 cm and occipital Left. Colonoscopy performed
by association with Muir-Torre syndrome, being normal. It manages external RT (60Gy) between August and September/05.
Subsequent checks by our department, physical examination shows no abnormalities. PET-CT was performed in May/10 (due
to iodinated contrast allergy), and inguinal appearing cervical lymphadenopathy malignant metabolic characteristics. Biopsy is
practiced them, not demonstrating malignancy. Year, is performed cervical ultrasound control, suggesting completion of PET-CT
for cervical lymph nodes hypoechoic. This time appear malignant lymph nodes generalized. It was decided to apply analytical
and serology extending them to rule out lymphoma or infectious process. Syphilis serology appears positive. After antibiotic
treatment normalizes PET-CT.
Conclusions. Sebaceous carcinoma is a rare adnexal tumor, presenting distance lymph node metastasis in many cases. The
locoregional radiotherapy after surgery can provide good results. The PET-CT is an excellent diagnostic tool in distant disease,
considering the false positive rate with benign infections or inﬂammations.
http://dx.doi.org/10.1016/j.rpor.2013.03.570
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Oncoproteomics is the study of proteins and their interactions in a cancer cell by proteomic technologies and has the potential to
revolutionize clinical practice, including cancer diagnosis. Recent technological advances in the analysis of the human genome
have opened the door to improving our primitive understanding of the gene expression patterns in cancer. The examination of the
phenotypic and (epi) genetic changes in cutaneous melanoma has identiﬁed several genes deemed central to the development
and progression of melanoma. The role of array-based high-throughput gene expression analysis in understanding the speciﬁc
genes involved as well as the pathways and the comparative gene expression patterns of primary and metastatic melanoma. The
development and clinical application of selective pharmacologic agents are also discussed.We identiﬁed several articles that have
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extensively studied the role of epigenetics in melanoma, further elucidating the complex processes involved in gene regulation
and expression. Other studies utilizing gene microarray analysis and other whole genome approaches reveal a wide array of
genes and expression patterns in human melanoma. Several genes have been identiﬁed as potential prognostic markers of
tumor progression and overall clinical outcome. High-throughput gene expression analysis has had a major impact in melanoma
research. Several gene expression platforms have provided insight into the gene expression patterns in melanoma. Such data
will provide foundations for the future development of prognostic markers and improved targeted therapies for patients with
melanoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.571
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Hidradenitis suppurativa (HS) is a chronic follicular occlusive disease (Hurley grade III and refractory) characterized by abscesses
and draining sinus tracts in apocrine gland-bearing regions. HS is frequently refractory to conventional management with oral
and topical treatments and may require surgical intervention. We report the outcomes of an exploratory study investigating the
effectiveness of radiation therapy for patients with refractory HS who failed multiple other therapies. Ten patients with Hurley
stage III and refractory were treated with radiation therapy to 25 affected sites (axillae, groin, perineal, perianal and infra/inter-
mammary folds). Each area was treated with electron beam radiation to a total dose of 20Gy in 4-5Gy fractions over 4 or 5
consecutive days. The average age was 40 years old and 99% had HS for longer than 5 years. By Hurley stage, 9 were stage III and
one was stage II. All patients previously failed topical and oral antibiotic therapy and other previous therapies included surgery
and inﬂiximab. All patients tolerated radiation well. Complete responses were observed ≥50% of the lesions and ≥90% had a
partial response after radiation therapy determined by patient report and clinical exam. Radiation therapy may be a promising
treatment for some patients with refractory HS. More basic research has to be initiated or strengthened and controlled clinical
multicenter studies have to be conducted not only to conﬁrm basic research data, but also to prove treatment efﬁcacy and
optimize treatment schedules (single and total dose, fractionation, and treatment time).
http://dx.doi.org/10.1016/j.rpor.2013.03.572
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Introduction. The expected yearly incidence of melanoma in the province of Cordoba is 51 cases. The optimal irradiation rate
has been estimated as 23% by groups of excellency based on scientiﬁc evidence. Since 2006 the Reina Sofía Hospital has had a
Melanoma Multidisciplinary Tumor Board.
Materials and methods. Descriptive retrospective study of the population of the province of Cordoba with skin melanoma referred
to the Department of Radiation Oncology.
Results. Scientiﬁc evidence shows that 11 patients diagnosed with melanoma per year should receive radiation therapy in the
province of Cordoba, which in 6 years would be 66 patients. During the period 2006–2011 the number of patients diagnosed
with melanoma and presented in the tumor board was 339. Of these patients, 29 (8.5%) were referred to the Department of
Radiation Oncology for evaluation. 58.6% were women. The median age was 71 years. Trunk (37.9%) and lower limbs (27.6%)
were the most frequent locations. Stage distribution was 12% in Stage 1, 48% in Stage II, and 16% and 24% in Stages III and IV
respectively. Surgery was the standard treatment option (89%), resulting in R1 in 76.9%. In 72.7% margins were expanded. The
sentinel node selective biopsy was performed in 26.1%, and resulted positive in 33.3%, provoking regional lymphadenectomy.
Locoregional failure occurred in 72.7%, and distant metastases in 77.3% of patients at the time of analysis. The median relapse
free survival and metastasis free survival were 9 and 26.5 months, respectively. Radiation therapy was administered in 62.1%
of referred patients. It was palliative in 88.9%. The median overall survival of this subgroup was of 25 months. 88% had passed
away at the moment of this study.
Conclusions. The number of patients diagnosed with melanoma referred for radiation treatment evaluation in the province of
Cordoba is inferior to that estimated as optimal.
http://dx.doi.org/10.1016/j.rpor.2013.03.573
